Infectious Diseases and Therapy

Aims and Scope

Infectious Diseases and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of infectious disease therapies and interventions, including vaccines and devices. Studies relating to diagnostic products and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.

Areas of focus include, but are not limited to, bacterial and fungal infections, viral infections (including HIV/AIDS and hepatitis), parasitological diseases, tuberculosis and other mycobacterial diseases, vaccinations and other interventions, and drug-resistance, chronic infections, epidemiology and tropical, emergent, pediatric, dermal and sexually-transmitted diseases.

The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports, trial protocols, short communications such as commentaries and editorials, and letters. The journal is read by a global audience and receives submissions from around the world. Infectious Diseases and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.

Rapid Publication: The journal aims for a 2-week peer review, and 3-4 weeks from acceptance to online publication. Please note that these timelines apply to our standard publication process. Any deviations, such as multiple rounds of peer review, multiple rounds of article proofs, or non-standard copyright arrangements may result in publication delays beyond these timelines. 

Open Access: All articles are published open access (CC-BY-NC)

Inclusivity: All scientifically sound research is considered be it positive, confirmatory or negative data. Research is considered from pre-clinical, clinical phase, real-world and health economics outcomes studies. Submissions relating to an international or country-specific audience are also welcome.

Personal Service: The journal’s team will reformat articles and upload submissions on behalf of authors, if necessary.

Digital Features and Plain Language Summaries: These peer-reviewed features are welcomed to help enhance the educational value of a manuscript (for more information see “Author Information – Guidelines for digital features and plain language summaries” under “Submission guidelines”).

Novel Article Types: We publish a wide range of novel article types beyond the traditional formats, including standalone podcast articles, Patient/Physician Perspective articles, and Summary of Research Articles. Please contact us for more information.

Publication Fees: Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €5950/$7675/ £5120. This fee includes: our rapid publication timelines; our personal concierge service providing authors with a dedicated and responsive point of contact and assisting with article submission and formatting; open access publication costs; and other offerings such as extensive article metrics upon request. Please note there is an additional fee for podcast articles.

Metrics: Individual article-level metrics are available on the article page, displaying number of accesses, citations and Altmetric score. Upon request, we can provide additional metrics including geographical readership, citation comparison, and additional digital feature metrics. 

Contact

For more information about the journal, including pre-submission enquiries, please contact david.gray@springer.com.

Co-Editor-in-Chief

• Michael J. Rybak, Pharm.D., MPH, Ph.D.,
• Alex Soriano

Journal Impact Factor

5.3 (2024)

5-year Journal Impact Factor

4.8 (2024)

Submission to first decision (median)

1 day

Downloads

1.4M (2025)